IL37 and breast cancer: A recent study verified that circulating IL-37 was highest in ER+/PR+/HER2+ breast cancer patients, compared to PR+, but not ER+/PR+ patients without metastasis, suggesting that IL-37 may influence the prognosis of breast cancer via ER+/PR+/HER2+ signaling (126).